With the goal of achieving an “AIDS-Free Generation,” the NIAID priority for HIV prevention research is to develop and test safe, effective, and acceptable biomedical and behavioral HIV prevention products and interventions that will help halt the spread of HIV infection globally. NIAID prevention research encompasses the development and testing of vaccines, new and improved combination prevention strategies, microbicides, treatment as prevention (TasP), and pre-exposure prophylaxis (PrEP). Underlying these efforts is behavioral and social science research to understand and address factors affecting the adoption and acceptance of any given approach.
NIAID-funded research has already led to the identification of highly effective non-vaccine prevention strategies that have the potential to significantly reduce HIV infection rates around the world. To improve upon these and develop additional strategies, NIAID non-vaccine prevention efforts seek to
Last Updated January 27, 2016